Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims
Executive Summary
Abuse-deterrent opioids address a serious unmet need and help differentiate brands from the field of generics, but so far Purdue’s OxyContin remains the only opioid on the market with abuse-deterrent claims, even though FDA recently approved two new opioid analgesics.
You may also be interested in...
Purdue Pharma: From Blockbuster Success To Bankrupt Villain
Purdue's rise and fall through opioids will likely end in bankruptcy, raising new questions around ongoing lawsuits and shining a light on the toll the opioid liability will leave on the industry.
Pfizer’s Troxyca ER Opioid Combo Faces Intravenous Abuse Concerns
More oxycodone was extracted from the combination product, potentially defeating the opioid-blunting effects of the naltrexone component and creating a hurdle to an abuse-deterrent claim.
Opioids: FDA Asks If Abuse-Deterrence Incentives Are In Line
Agency chief counsel says exclusivity for better formulations may need to be considered.